Search This Blog

Thursday, June 13, 2019

FDA OKs Amgen’s Herceptin biosimilar

The FDA approves Amgen’s (AMGN +0.4%) KANJINTI (trastuzumab-anns), its biosimilar to Roche’s (OTCQX:RHHBY +0.4%) Herceptin (trastuzumab).
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)